The Experts below are selected from a list of 165 Experts worldwide ranked by ideXlab platform
Ashley Irish - One of the best experts on this subject based on the ideXlab platform.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of Medical Virology, 2017Co-Authors: Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley Irish, P B PriceAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P < 0.001), and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However, the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (P = 0.068), with age (P = 0.013), gender (P < 0.0001), and transplantation (P < 0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible as an approach to reduce vascular disease. J. Med. Virol. 89:177-181, 2017. © 2016 Wiley Periodicals, Inc.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of medical virology, 2016Co-Authors: Patricia Price, Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley IrishAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P
P B Price - One of the best experts on this subject based on the ideXlab platform.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of Medical Virology, 2017Co-Authors: Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley Irish, P B PriceAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P < 0.001), and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However, the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (P = 0.068), with age (P = 0.013), gender (P < 0.0001), and transplantation (P < 0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible as an approach to reduce vascular disease. J. Med. Virol. 89:177-181, 2017. © 2016 Wiley Periodicals, Inc.
-
short communication do Cytomegalovirus Antibody levels associate with age related syndromes in hiv patients stable on antiretroviral therapy
AIDS Research and Human Retroviruses, 2016Co-Authors: Samantha J Brunt, Silvia Lee, Lucette A Cysique, Sally Burrows, Bruce J Brew, P B PriceAbstract:HIV(+) persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of Cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV(+) participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate Antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate Antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate Antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R(2) = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV(+) patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.
Silvia Lee - One of the best experts on this subject based on the ideXlab platform.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of Medical Virology, 2017Co-Authors: Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley Irish, P B PriceAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P < 0.001), and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However, the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (P = 0.068), with age (P = 0.013), gender (P < 0.0001), and transplantation (P < 0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible as an approach to reduce vascular disease. J. Med. Virol. 89:177-181, 2017. © 2016 Wiley Periodicals, Inc.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of medical virology, 2016Co-Authors: Patricia Price, Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley IrishAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P
-
short communication do Cytomegalovirus Antibody levels associate with age related syndromes in hiv patients stable on antiretroviral therapy
AIDS Research and Human Retroviruses, 2016Co-Authors: Samantha J Brunt, Silvia Lee, Lucette A Cysique, Sally Burrows, Bruce J Brew, P B PriceAbstract:HIV(+) persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of Cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV(+) participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate Antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate Antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate Antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R(2) = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV(+) patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.
Robert H Rubin - One of the best experts on this subject based on the ideXlab platform.
-
preemptive ganciclovir therapy to prevent Cytomegalovirus disease in Cytomegalovirus Antibody positive renal transplant recipients a randomized controlled trial
Annals of Internal Medicine, 1995Co-Authors: Patricia L Hibberd, Nina Tolkoffrubin, David J Conti, F Stuart, J R Thistlethwaite, J F Neylan, David R Snydman, Richard B Freeman, M I Lorber, Robert H RubinAbstract:. Objective : To determine whether preemptive ganciclovir therapy administered daily during antilymphocyte Antibody therapy can prevent Cytomegalovirus disease in renal transplant recipients who are positive for Cytomegalovirus Antibody. . Design : Randomized, controlled, multicenter trial. . Setting : 6 university-affiliated transplantation centers. . Patients : 113 renal transplant recipients who were positive for Cytomegalovirus Antibody. . Intervention : Patients were randomly assigned to receive either 1) ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte Antibody therapy was administered or 2) no antiCytomegalovirus therapy. . Measurements : Patients were observed for 6 months after completion of antilymphocyte Antibody therapy for development of Cytomegalovirus disease and Cytomegalovirus viremia. . Results : Cytomegalovirus disease occurred in 14% of patients (9 of 64) who received preemptive ganciclovir therapy and in 33% of controls (16 of 49) (P = 0.018). Cytomegalovirus was isolated from buffy-coat specimens from 17% of patients (11 of 64) receiving preemptive ganciclovir and from 35% of controls (17 of 49) (P = 0.03). Controlling for the reason (induction or treatment of rejection) for using antilymphocyte antibodies in a Cox proportional hazards model, we found that preemptive ganciclovir still protected against Cytomegalovirus disease (adjusted relative risk, 0.27 ; 95% Cl, 0.12 to 0.64). No adverse events were attributed to preemptive ganciclovir therapy during or within 6 months of its administration. . Conclusions : Preemptive ganciclovir therapy administered daily during courses of treatment with antilymphocyte antibodies reduced the excessive occurrence of Cytomegalovirus disease in renal transplant recipients who were positive for Cytomegalovirus Antibody. This approach, which links the most potent immunosuppression to intensive antimicrobial therapy, allows preventive therapy to be given to those patients at greatest risk for developing infectious complications. These patients are likely to benefit most from the preventive strategy.
-
symptomatic Cytomegalovirus disease in the Cytomegalovirus Antibody seropositive renal transplant recipient treated with okt3
Transplantation, 1992Co-Authors: Patricia L Hibberd, Nina Tolkoffrubin, A B Cosimi, Robert T Schooley, Deborah Isaacson, M Doran, Angela Delvecchio, Francis L Delmonico, Hugh Auchincloss, Robert H RubinAbstract:A prospective study to investigate risk factors for CMV disease was conducted in 94 renal transplant recipients. CMV disease was defined as either unexplained fever for greater than 3 days with viremia or unexplained fever for greater than 3 days with isolation of CMV from the urine or throat wash and at least one of the following: leukopenia, elevated serum alanine aminotransferase, or biopsy-proved invasive tissue infection of the lung or gastrointestinal tract. Fifty-three patients received immunosuppressive regimens consisting of prednisone and cyclosporine, with or without azathioprine. The remaining 41 patients were treated with these agents plus OKT3 (21 received OKT3 to treat rejection, 20 received OKT3 prophylactically). Thirty-seven patients were at minimal risk of CMV disease (donor and recipient seronegative for CMV); 12 patients were at risk of primary disease (donor seropositive, recipient seronegative), and 45 were at risk of reactivation disease (recipient seropositive at the time of transplantation). The incidences of CMV disease in the 3 groups were 0%, 58%, and 36%, respectively. Although the incidence of CMV disease in patients at risk of primary disease was not influenced by the immunosuppressive regimen, immunosuppression had a profound effect on the occurrence of CMV disease in CMV-seropositive transplant recipients. The incidence of CMV disease in those receiving OKT3 was 59%; but only 21% in those who did not receive OKT3. OKT3 increased the risk of CMV disease five-fold (odds ratio 5.2 (95% confidence limits 1.4-17.5)). In the CMV-seropositive patient, OKT3 was also the most important predictor of CMV disease by multivariate analysis (P less than 0.002). A pilot study of preemptive therapy with ganciclovir (2.5 mg/kg daily during OKT3 therapy) in 17 patients decreased the incidence of CMV disease without appreciable toxicity.
Jacquita S. Affandi - One of the best experts on this subject based on the ideXlab platform.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of Medical Virology, 2017Co-Authors: Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley Irish, P B PriceAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P < 0.001), and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However, the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (P = 0.068), with age (P = 0.013), gender (P < 0.0001), and transplantation (P < 0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible as an approach to reduce vascular disease. J. Med. Virol. 89:177-181, 2017. © 2016 Wiley Periodicals, Inc.
-
Cytomegalovirus Antibody and vascular pathology in renal transplant recipients
Journal of medical virology, 2016Co-Authors: Patricia Price, Silvia Lee, Jacquita S. Affandi, Richard Parsons, Louise H. Naylor, Gerald F. Watts, Ashley IrishAbstract:Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV Antibody increased with age, were higher in transplant recipients than healthy controls (P
